Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 17, 2023 07:00 ET | Source: Century Therapeutics, Inc.

Century Therapeutics to Present at Chardan’s 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit

PHILADELPHIA, April 17, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell...
April 12, 2023 08:30 ET | Source: Century Therapeutics, Inc.

Century Therapeutics Announces Leadership Changes

– Lalo Flores, Ph.D., steps down as Chief Executive Officer and member of Board of Directors; Greg Russotti, Ph.D., Chief Technology Officer, assumes role of ad-interim Chief Executive Officer – –...
March 16, 2023 07:30 ET | Source: Century Therapeutics, Inc.

Century Therapeutics Reports Full Year 2022 Financial Results and Provides Business Updates

- Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell lymphomas underway - - Ended 2022 with cash, cash equivalents, and investments of $367.4 million; Cash runway expected...
March 15, 2023 16:01 ET | Source: Century Therapeutics, Inc.

Century Therapeutics to Present at the AACR Annual Meeting 2023

PHILADELPHIA, March 15, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell...
February 21, 2023 07:00 ET | Source: Century Therapeutics, Inc.

Century Therapeutics to Present at Upcoming Investor Conferences

PHILADELPHIA, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell...
February 08, 2023 07:30 ET | Source: Century Therapeutics, Inc.

Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 ELiPSE-1 Trial Evaluating CNTY-101 in Relapsed or Refractory CD19 Positive B-cell Lymphomas

– CNTY-101 is the first cell therapy product candidate engineered with six precision gene edits including a CD19-CAR, Allo-Evasion™ technology, IL-15 cytokine support and a safety switch – –...
February 01, 2023 07:00 ET | Source: Century Therapeutics, Inc.

Century Therapeutics to Present at Upcoming Investor Conferences

PHILADELPHIA, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...
January 05, 2023 16:01 ET | Source: Century Therapeutics, Inc.

Century Therapeutics Announces Internal Portfolio Prioritization to Extend Cash Runway Into 2026

- Prioritization allows for acceleration of key programs including CNTY-107 in Nectin-4+ tumors, while de-prioritizing further investment in CNTY-103 for glioblastoma - - Employee headcount reduced...
January 04, 2023 07:00 ET | Source: Century Therapeutics, Inc.

Century Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

PHILADELPHIA, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...
November 22, 2022 07:00 ET | Source: Century Therapeutics, Inc.

Century Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference

PHILADELPHIA, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...